{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.4","upperLimit":"42.3","value":"32.1"},{"groupId":"OG001","lowerLimit":"15","upperLimit":"36","value":"24.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.02. DR was calculated for the subgroup of participants with a confirmed objective tumor response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG000","title":"Crizotinib"},{"description":"Pemetrexed 500 mg/m\\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"FAS included all participants who were randomized to study treatment. Here 'N' (number of participant analyzed) signifies participants with objective tumor response.","reportingStatus":"POSTED","timeFrame":"Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks)","title":"Duration of Response (DR)","type":"SECONDARY","unitOfMeasure":"weeks"}